WOODSTOCK, Ga.–(Business WIRE)–Sonoma Prescribed drugs, Inc. (Nasdaq: SNOA), a world-wide healthcare leader developing and making patented Microcyn® engineering primarily based stabilized hypochlorous acid (HOCl) products and solutions for a wide assortment of applications, like wound, eye, oral and nasal treatment, disinfectant use and dermatological problems, right now announced that it has launched two new dental products and solutions. OroGenix Oral Cleanliness Rinse is Sonoma’s next dental product in the U.S., and was designed with its spouse Gabriel Science, LLC. Also, in Switzerland, Sonoma and its partner, Healthcare Devices Methods, have launched Microdacyn® Oral Care for each professional and customer use.
Just after productively launching Endocyn® for root canal irrigation in December 2020, Sonoma’s second dental item in the U.S. is an oral cleanliness rinse. OroGenix Oral Cleanliness Rinse works by using Sonoma’s patented Microcyn® technology to cleanse enamel, gums, and mouth.
For extra data and to invest in OroGenix Oral Hygiene Rinse you should go to http://sonomapharma.com/orogenix-oral/.
In Europe, Microdacyn60® Oral Treatment is intended to fight oral and pharyngeal infections and swelling, and reduce agony and coughing. Sonoma’s dental goods do not stain the tooth, and are created using the harmless and effective proof-based mostly Microcyn® know-how. For far more info and to purchase Microdacyn60 Oral Care please stop by http://www.medicalsol.ch/produkte/wundbehandlung/microdacyn60-oral-treatment/.
“We think the OroGenix Oral Cleanliness Rinse and the Microcyn relatives of hypochlorous acid merchandise will enable dentists and their patients reach balanced gums, enamel, and oral cavity,” explained Dr. Mark Fontenot, managing member at Gabriel Science, LLC.
“Microdacyn60® Oral Care delivers a excellent option for oral and throat care. Not only in dentistry, but also in typical oral and pharyngeal care these kinds of as intubated clients, we see the fantastic advantages of Microdacyn60 Oral Care as an alternative for greatly used chlorhexidine-based products,” commented Mr. Edgar Sommer, Typical Manager at Clinical Technique Remedies.
“We are delighted to provide the oral rinse to dental places of work in the U.S., and for each expert and client use in Europe. Gabriel Science and Clinical Process Options are excellent companions for advancing our dental and oral care line of goods,” stated Bruce Thornton, COO of Sonoma Prescribed drugs. “Our proprietary Microcyn technologies is genuinely the upcoming-era formulation in terms of outstanding antimicrobial effect, shelf stability and basic safety.”
About Gabriel Science, LLC
Gabriel Science, LLC is a lifetime science organization dedicated to offering highly developed therapies and products and solutions for the professional administration of oral, dental, and head and neck circumstances. In collaboration with foremost clinicians, Gabriel Science distributes and sells proprietary products for tissue regeneration, wound therapeutic, and oral, head and neck disorder management. Gabriel Science is a U.S.-based mostly business located in Niwot, Colorado (www.gabrielscience.com).
About Medical Techniques Remedies
Medical Techniques Answer AG is a Swiss Medtech corporation founded in 2006. The firm offers added price modern merchandise in the fields of Oral Care, Wound administration, Surgical procedures and Anaesthesia/ICU. The company’s skills inside many professional medical spots will make Health-related Devices Resolution a accurate beneficial partner in locating the most effective- and economically suitable solutions in just complicated medical scenarios. (www.medicalsol.ch)
About Sonoma Prescription drugs, Inc.
Sonoma Pharmaceuticals is a worldwide healthcare leader for developing and making stabilized hypochlorous acid (HOCl) merchandise for a extensive range of applications, such as wound treatment, animal wellbeing care, eye care, nasal treatment, oral care, disinfectant use and dermatological ailments. The company’s goods cut down bacterial infections, itch, agony, scarring and destructive inflammatory responses in a harmless and helpful fashion. In-vitro and scientific scientific studies of hypochlorous acid (HOCl) display it to have spectacular antipruritic, antimicrobial, antiviral and anti-inflammatory attributes. Sonoma’s stabilized HOCl right away relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the region addressed aiding the human body in its organic healing process. The company’s goods are offered both straight or by means of associates in 54 nations around the world worldwide and the business actively seeks new distribution companions. The company’s principal business is in Woodstock, Georgia, with producing functions in Latin The united states. European marketing and gross sales are headquartered in Roermond, Netherlands. More information can be observed at www.sonomapharma.com. For partnership prospects, remember to get hold of email@example.com.
Other than for historical data herein, issues established forth in this press release are ahead-on the lookout inside of the meaning of the “safe harbor” provisions of the Non-public Securities Litigation Reform Act of 1995, like statements about the industrial and technological innovation development and foreseeable future fiscal functionality of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are discovered by the use of text this kind of as “continue,” “develop” and “expand,” amid other individuals. Ahead-on the lookout statements in this push launch are subject matter to particular pitfalls and uncertainties inherent in the company’s small business that could cause genuine final results to differ, which includes this sort of challenges that regulatory scientific and guideline developments may possibly improve, scientific knowledge could not be adequate to meet regulatory specifications or receipt of demanded regulatory clearances or approvals, medical outcomes may possibly not be replicated in actual patient configurations, security supplied by the company’s patents and patent applications may well be challenged, invalidated or circumvented by its rivals, the offered marketplace for the company’s items will not be as big as expected, the company’s solutions will not be equipped to penetrate one or more specific markets, revenues will not be adequate to meet up with the company’s cash demands, fund even more advancement, as nicely as uncertainties relative to the COVID-19 pandemic and economic improvement, varying item formulations and a multitude of assorted regulatory and marketing requirements in different nations around the world and municipalities, and other hazards in depth from time to time in the company’s filings with the Securities and Exchange Fee. The business disclaims any obligation to update these forward-seeking statements, other than as required by law.
Sonoma Pharmaceuticals™, Microdacyn60® and Microcyn® are trademarks or registered logos of Sonoma Prescription drugs, Inc. All other logos and assistance marks are the home of their respective homeowners.